See more : PT Panca Global Kapital Tbk (PEGE.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Perspective Therapeutics, Inc. (CATX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Perspective Therapeutics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- AURELIUS Equity Opportunities SE & Co. KGaA (AR4.DE) Income Statement Analysis – Financial Results
- Arabian Mills for Food Products (2285.SR) Income Statement Analysis – Financial Results
- ACTIA Group S.A. (ATI.PA) Income Statement Analysis – Financial Results
- Tonymoly Co., Ltd (214420.KS) Income Statement Analysis – Financial Results
- Medacta Group SA (0A05.L) Income Statement Analysis – Financial Results
Perspective Therapeutics, Inc. (CATX)
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.43M | 7.10M | 10.80M | 10.05M | 9.68M | 7.31M | 5.92M | 4.76M | 4.77M | 4.61M | 4.22M | 4.53M | 5.07M | 5.24M | 5.29M | 5.42M | 7.16M | 5.74M | 1.99M | 201.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.85M | 8.26M | 7.82M | 6.79M |
| Cost of Revenue | 0.00 | 5.47M | 6.18M | 4.93M | 4.56M | 4.27M | 4.08M | 3.92M | 4.64M | 4.44M | 4.42M | 4.38M | 4.37M | 4.08M | 4.56M | 5.77M | 7.31M | 5.79M | 3.82M | 1.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.68M | 7.46M | 6.99M | 6.42M |
| Gross Profit | 1.43M | 1.63M | 4.62M | 5.12M | 5.12M | 3.05M | 1.84M | 838.00K | 129.15K | 167.39K | -196.47K | 150.18K | 703.20K | 1.16M | 725.80K | -353.33K | -151.43K | -54.60K | -1.82M | -1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.16M | 795.61K | 822.28K | 367.89K |
| Gross Profit Ratio | 100.00% | 23.00% | 42.76% | 50.94% | 52.93% | 41.66% | 31.10% | 17.60% | 2.71% | 3.63% | -4.66% | 3.32% | 13.87% | 22.09% | 13.73% | -6.52% | -2.12% | -0.95% | -91.30% | -630.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.84% | 9.63% | 10.52% | 5.42% |
| Research & Development | 21.31M | 2.60M | 2.58M | 1.43M | 1.13M | 1.47M | 1.75M | 965.00K | 528.05K | 614.77K | 668.80K | 627.11K | 730.58K | 465.33K | 340.96K | 958.67K | 1.36M | 1.35M | 450.43K | 137.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 20.97M | 10.87M | 6.62M | 4.69M | 4.57M | 4.17M | 4.17M | 3.92M | 3.79M | 2.40M | 2.49M | 2.29M | 2.36M | 2.42M | 2.44M | 2.79M | 7.29M | 8.30M | 4.92M | 0.00 | 30.00K | 9.10K | 19.02K | 7.58K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 97.00K | 3.23M | 2.80M | 2.44M | 2.98M | 2.68M | 2.66M | 2.31M | 1.35M | 1.49M | 1.23M | 1.30M | 1.22M | 1.23M | 1.95M | 2.37M | 0.00 | 0.00 | 0.00 | 0.00 | -20.91K | 9.93K | -11.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.06M | 14.21M | 9.43M | 7.13M | 7.55M | 6.85M | 6.83M | 6.23M | 5.14M | 3.89M | 3.72M | 3.59M | 3.57M | 3.66M | 4.39M | 5.16M | 7.29M | 8.30M | 4.92M | 2.57M | 9.10K | 19.02K | 7.58K | 7.58K | 0.00 | 15.53K | 221.88K | 1.11M | 2.59M | 1.24M | 1.23M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -73.00K | 2.00K | 0.00 | -48.00K | -456.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.99K | 15.57K | 0.00 | 207.30K | 942.00 | 317.97K | 316.74K | 406.92K |
| Operating Expenses | 42.38M | 17.43M | 12.01M | 8.56M | 8.60M | 8.33M | 8.57M | 7.15M | 5.21M | 4.50M | 4.39M | 4.22M | 4.30M | 4.12M | 4.73M | 6.12M | 8.65M | 9.65M | 5.37M | 2.71M | 9.10K | 19.02K | 7.58K | 15.57K | 14.15K | 15.53K | 222.83K | 1.43M | 2.91M | 1.65M | 1.54M |
| Cost & Expenses | 42.38M | 22.90M | 18.19M | 13.49M | 13.16M | 12.59M | 12.65M | 11.07M | 9.85M | 8.94M | 8.81M | 8.59M | 8.67M | 8.20M | 9.29M | 11.89M | 15.96M | 15.44M | 9.19M | -4.18M | 9.10K | 19.02K | 7.58K | 15.57K | 14.15K | 15.53K | 222.83K | 8.11M | 10.37M | 8.64M | 7.96M |
| Interest Income | 934.00K | 1.12M | 119.00K | 59.00K | 30.00K | 108.00K | 29.00K | 118.00K | 218.15K | 282.75K | 12.11K | 664.00 | 747.00 | 3.38K | 11.43K | 111.05K | 0.00 | 0.00 | 0.00 | 2.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 84.00K | 0.00 | 119.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 950.00 | 2.21K | 883.00 | 7.00 | 61.68K | 216.61K | 36.39K | 75.31K | 274.00K | 0.00 | 1.02M | 167.49K | 0.00 | 2.10K | 41.01K | 51.50K | 0.00 | 0.00 | -12.44K | 0.00 | 163.27K | 66.96K | 108.63K |
| Depreciation & Amortization | 981.00K | 344.00K | 248.00K | 9.00K | 147.00K | -24.00K | 80.00K | 68.00K | 470.85K | 576.38K | 685.40K | 739.15K | 847.12K | 888.57K | 996.88K | 1.21M | 1.06M | 715.25K | 655.33K | 143.04K | 0.00 | 84.85K | -41.01K | -51.50K | 250.68K | -51.50K | 942.00 | 317.97K | 316.74K | 407.42K | 308.83K |
| EBITDA | -39.96M | -14.84M | -7.39M | -3.43M | -3.48M | -5.30M | -6.70M | -6.19M | -4.39M | -4.05M | -3.89M | -3.33M | -2.92M | -2.07M | -3.01M | -5.54M | -7.47M | -8.98M | -6.15M | -3.96M | -9.10K | -19.02K | -7.58K | -15.57K | -14.15K | -15.53K | -234.32K | 13.87K | -2.69M | -436.43K | -1.78M |
| EBITDA Ratio | -2,786.61% | -208.87% | -68.47% | -34.10% | -35.91% | -72.49% | -113.12% | -129.99% | -92.11% | -87.99% | -92.22% | -73.53% | -57.60% | -39.53% | -56.98% | -102.21% | -104.32% | -156.58% | -308.60% | -1,962.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.18% | -32.56% | -5.58% | -26.22% |
| Operating Income | -40.94M | -15.18M | -7.39M | -3.44M | -3.48M | -5.28M | -6.73M | -6.31M | -5.08M | -4.34M | -4.59M | -4.07M | -3.60M | -2.96M | -4.01M | -6.47M | -8.80M | -9.70M | -7.20M | -3.98M | -9.10K | -19.02K | -7.58K | -15.57K | -14.15K | -15.53K | -222.83K | -260.71K | -2.11M | -827.94K | -1.17M |
| Operating Income Ratio | -2,855.02% | -213.71% | -68.47% | -34.19% | -35.91% | -72.16% | -113.61% | -132.47% | -106.56% | -94.13% | -108.75% | -89.88% | -70.95% | -56.56% | -75.84% | -119.43% | -122.97% | -169.04% | -360.79% | -1,974.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3.32% | -25.55% | -10.59% | -17.21% |
| Total Other Income/Expenses | 835.00K | 512.00K | 119.00K | 50.00K | 30.00K | 134.00K | 29.00K | 27.00K | 154.00K | 374.61K | -1.38M | 210.00K | 170.00K | 334.00K | 0.00 | 274.00K | -274.00K | 0.00 | -385.51K | -285.99K | -2.10K | -2.10K | -41.01K | -51.50K | 0.00 | 0.00 | 12.44K | 43.40K | 895.74K | 15.91K | 920.60K |
| Income Before Tax | -40.11M | -14.67M | -7.27M | -3.39M | -3.45M | -5.14M | -6.70M | -6.16M | -4.71M | -3.68M | -5.96M | -3.86M | -3.43M | -2.84M | 0.00 | -6.20M | -9.08M | 0.00 | -8.22M | -4.27M | -11.20K | -60.03K | -59.08K | -59.08K | 0.00 | 0.00 | -3.09K | -423.98K | -2.15M | -936.57K | -435.09K |
| Income Before Tax Ratio | -2,796.79% | -206.50% | -67.36% | -33.69% | -35.60% | -70.33% | -113.12% | -129.43% | -98.77% | -79.91% | -141.24% | -85.22% | -67.60% | -54.25% | 0.00% | -114.37% | -126.79% | 0.00% | -412.08% | -2,116.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.40% | -26.03% | -11.98% | -6.41% |
| Income Tax Expense | -2.65M | 0.00 | -119.00K | -199.00K | -177.00K | -294.00K | -29.00K | -145.00K | -371.20K | -655.14K | 1.37M | -210.66K | -109.07K | -120.78K | 24.96K | -309.74K | -245.21K | -94.68K | 1.02M | 0.00 | -86.96K | -84.85K | 41.01K | 51.50K | -250.68K | 51.50K | -942.00 | 2.10K | 2.00K | 2.60K | 2.50K |
| Net Income | -46.51M | -14.67M | -7.15M | -3.19M | -3.27M | -4.85M | -6.70M | -6.16M | -4.71M | -3.68M | -5.96M | -3.86M | -3.49M | -2.84M | -4.03M | -6.16M | -8.56M | -9.61M | -8.22M | -4.27M | 75.76K | -60.03K | -59.08K | 235.11K | -65.65K | 1.82M | -139.55K | -426.08K | -2.15M | -939.17K | -437.59K |
| Net Income Ratio | -3,243.24% | -206.50% | -66.26% | -31.71% | -33.77% | -66.31% | -113.12% | -129.43% | -98.77% | -79.91% | -141.24% | -85.22% | -68.80% | -54.25% | -76.31% | -113.71% | -119.54% | -167.39% | -412.08% | -2,116.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.43% | -26.06% | -12.01% | -6.45% |
| EPS | -1.40 | -0.10 | -0.05 | -0.03 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 | -0.14 | -0.11 | -0.12 | -0.11 | -0.18 | -0.27 | -0.37 | -0.54 | -0.68 | -197.24 | 0.03 | -0.07 | -0.18 | 0.60 | -0.20 | 5.41 | -0.42 | -1.29 | -6.63 | -3.27 | -1.52 |
| EPS Diluted | -1.40 | -0.10 | -0.05 | -0.03 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 | -0.14 | -0.11 | -0.12 | -0.11 | -0.18 | -0.27 | -0.37 | -0.54 | -0.68 | -197.24 | 0.03 | -0.07 | -0.18 | 0.60 | -0.20 | 5.41 | -0.42 | -1.29 | -6.63 | -3.27 | -1.52 |
| Weighted Avg Shares Out | 26.76M | 142.10M | 141.99M | 103.84M | 67.60M | 67.04M | 55.16M | 55.02M | 55.01M | 54.88M | 42.68M | 34.42M | 28.62M | 25.13M | 22.96M | 22.94M | 23.03M | 17.83M | 12.05M | 21.65K | 2.36M | 804.04K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 324.73K | 287.61K | 287.61K |
| Weighted Avg Shares Out (Dil) | 26.76M | 142.10M | 141.99M | 103.84M | 67.60M | 67.04M | 55.16M | 55.02M | 55.02M | 54.88M | 42.68M | 34.42M | 28.62M | 25.13M | 22.96M | 22.94M | 23.03M | 17.83M | 12.05M | 21.65K | 2.36M | 804.04K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 324.73K | 287.61K | 287.61K |
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will...
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced initial results from its ongoing Phase 1/2a clinical trial...
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results...
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results
SEATTLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc . (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced third quarter financial...
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November
SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will...
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates on the Company's radiopharmaceutical programs being...
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey
SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today is celebrating the first shipment and patient dosing from...
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research
SEATTLE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a...
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a...
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day
SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that its senior management will participate in panel...
Source: https://incomestatements.info
Category: Stock Reports